European Archives - Page 34 of 1145 - European Medical Journal

Diu Nguyen

Hema Now: Episode 16: A Journey Through Leukaemia Research

Diu Nguyen, Lecturer and Group Leader at the Centre for Haemato-Oncology, Barts Cancer Institute, joins the podcast to discuss breakthroughs in acute myeloid leukaemia (AML) research

SGLT2 Inhibitors Reduce Hyperkalaemia Risk in RAASi Use

SGLT2 inhibitors reduce hyperkalemia risk, aiding RAASi continuity in high-risk patients.

NHS Opt-Out Testing Detects Hepatitis: EASL 2025

The study concludes that ED-based opt-out testing is both effective and acceptable in detecting hepatitis.

Shingles Vaccine Tied to Lower Cardiovascular Risk

A new study has revealed a potential link between live zoster vaccination and a reduced risk of cardiovascular disease.

Persistent Lung and Heart Inflammation Found in Majority of Long COVID Patients

Read how a recent study showed widespread cardiopulmonary abnormalities in long COVID patients one year post-infection.

Personalising MDMA Therapy with Negative Affect Circuit Activity

Baseline brain circuit activity predicts who benefits most from MDMA, paving the way for personalised psychiatric treatments.

Menstrual Cycle May Influence Inflammation in Women with Sickle Cell Disease

A recent study has found that women with sickle cell disease experience higher inflammation during the follicular phase of their menstrual cycle, which may explain the timing of pain episodes and offer insight into more personalised care.

Adequate mitomycin C can effectively reduce recurrence and progression in patients with IR NMIBC – the value of maintenance therapy*

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic…

Semaglutide Shows Promise in Treating MASH and Liver Fibrosis

Semaglutide significantly improves liver inflammation and fibrosis in MASH patients, offering new hope for clinical management.

New Screening Model Enhances Hepatitis Care Access: EASL 2025

The study concludes that decentralised and person-centred hepatitis screening is effective and essential.